phosphorylcholine has been researched along with Leishmaniasis in 75 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Leishmaniasis: A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of miltefosine in cutaneous leishmaniasis has been addressed in a few clinical trials." | 8.88 | Miltefosine and cutaneous leishmaniasis. ( Machado, PR; Penna, G, 2012) |
| " Since 1998 Indian researchers have conducted clinical trials evaluating hexadecylphosphocoline (miltefosine) in patients with visceral leishmaniasis and in 1999 clinical studies were initiated in Colombia in patients with cutaneous leishmaniasis." | 8.83 | [Oral miltefosine to treat leishmaniasis]. ( Soto, J; Soto, P, 2006) |
| " Beginning in 1998, Indian researchers conducted several trials with hexadecylphosphocholine (miltefosine) in patients with visceral leishmaniasis, and in 1999, clinical studies were initiated in Colombia for cutaneous disease." | 8.83 | Miltefosine: oral treatment of leishmaniasis. ( Soto, J; Soto, P, 2006) |
| "Miltefosine is an important drug for the treatment of leishmaniasis; however, its mechanism of action is still poorly understood." | 7.88 | Leishmania parasitophorous vacuole membranes display phosphoinositides that create conditions for continuous Akt activation and a target for miltefosine in Leishmania infections. ( Huyghues Despointes, CE; Kima, PE; Prasad, S; Young, J; Zhang, N, 2018) |
| "Oral miltefosine was administered to 39 human immunodeficiency virus (HIV)-infected patients with leishmaniasis for whom standard leishmaniasis treatment had failed." | 7.72 | Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. ( Bommer, W; Engel, KR; Fischer, C; Sindermann, H, 2004) |
| "Miltefosine has not been readily available in the United States due to marketing delays and is expected to become available later this year." | 6.52 | Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine. ( Fujinami, N; Shah, PJ; Vakil, NH, 2015) |
| "Miltefosine is an alkylphosphocholine drug with demonstrated activity against various parasite species and cancer cells as well as some pathogenic bacteria and fungi." | 6.48 | Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. ( Balasegaram, M; Beijnen, JH; de Vries, PJ; Dorlo, TP, 2012) |
| "Miltefosine was originally formulated and registered as a topical treatment for cutaneous cancers." | 6.43 | Development of miltefosine as an oral treatment for leishmaniasis. ( Engel, J; Sindermann, H, 2006) |
| "Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas." | 5.36 | Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010) |
| "Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models." | 5.32 | Miltefosine (Impavido): the first oral treatment against leishmaniasis. ( Bommer, W; Croft, SL; Eibl, HJ; Engel, J; Engel, KR; Sindermann, H; Unger, C, 2004) |
| "The use of miltefosine in cutaneous leishmaniasis has been addressed in a few clinical trials." | 4.88 | Miltefosine and cutaneous leishmaniasis. ( Machado, PR; Penna, G, 2012) |
| " Since 1998 Indian researchers have conducted clinical trials evaluating hexadecylphosphocoline (miltefosine) in patients with visceral leishmaniasis and in 1999 clinical studies were initiated in Colombia in patients with cutaneous leishmaniasis." | 4.83 | [Oral miltefosine to treat leishmaniasis]. ( Soto, J; Soto, P, 2006) |
| "Although three new drugs or drug formulations, liposomal amphotericin B (AmBisome), miltefosine and paromomycin should be available for the treatment of visceral leishmaniasis (VL) within the next year, they all suffer from limitations of either cost, specific toxicities or parenteral administration." | 4.83 | Current scenario of drug development for leishmaniasis. ( Croft, SL; Seifert, K; Yardley, V, 2006) |
| "Future issues that need to be addressed for miltefosine are efficacy against non-Indian visceral leishmaniasis, efficacy in HIV-coinfected patients, efficacy against the many forms of cutaneous and mucosal disease, effectiveness under clinical practice conditions, generation of drug resistance and the need to provide a second antileishmanial agent to protect against this disastrous event, and the ability to maintain reproductive contraceptive practices under routine clinical conditions." | 4.83 | Miltefosine: issues to be addressed in the future. ( Berman, J; Bryceson, AD; Croft, S; Engel, J; Gutteridge, W; Karbwang, J; Sindermann, H; Soto, J; Sundar, S; Urbina, JA, 2006) |
| " Beginning in 1998, Indian researchers conducted several trials with hexadecylphosphocholine (miltefosine) in patients with visceral leishmaniasis, and in 1999, clinical studies were initiated in Colombia for cutaneous disease." | 4.83 | Miltefosine: oral treatment of leishmaniasis. ( Soto, J; Soto, P, 2006) |
| "In this review we have summarized published data on two new compounds, which can represent important antiparasitic drugs in the near future, nitazoxanide for treatment of intestinal parasitic infections including cryptosporidiosis and miltefosine for oral treatment of visceral leishmaniasis." | 4.82 | [New drugs for treatment of parasitic infections]. ( Lobovská, A; Nohýnková, E, 2003) |
| "The obtained results indicated that dineolignans 1 and 2 could be considered as a scaffold for the design of novel and selective drug candidates for the treatment of leishmaniasis." | 3.91 | Antileishmanial activity and ultrastructural changes of related tetrahydrofuran dineolignans isolated from Saururus cernuus L. (Saururaceae). ( Barbosa, H; Bezerra-Souza, A; Brito, JR; Ferreira, EA; Lago, JHG; Laurenti, MD; Passero, LFD; Romoff, P, 2019) |
| "Increasing drug resistance towards first line antimony-derived compounds has forced the introduction of novel therapies in leishmaniasis endemic areas including amphotericin B and miltefosine." | 3.88 | High-throughput Cos-Seq screen with intracellular Leishmania infantum for the discovery of novel drug-resistance mechanisms. ( Bresson, E; Fernandez-Prada, C; Leprohon, P; Ouellette, M; Plourde, M; Roy, G; Sharma, M, 2018) |
| "Miltefosine is an important drug for the treatment of leishmaniasis; however, its mechanism of action is still poorly understood." | 3.88 | Leishmania parasitophorous vacuole membranes display phosphoinositides that create conditions for continuous Akt activation and a target for miltefosine in Leishmania infections. ( Huyghues Despointes, CE; Kima, PE; Prasad, S; Young, J; Zhang, N, 2018) |
| " In this study, we explored the role of human macrophage transporters in the intracellular accumulation and antileishmanial activity of miltefosine (MLF), the only oral drug available for the treatment of visceral and cutaneous leishmaniasis (CL)." | 3.83 | Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: IMPACT ON INTRACELLULAR SURVIVAL OF LEISHMANIA (VIANNIA) PANAMENSIS. ( Dohmen, LC; Dorlo, TP; Gomez, MA; Gregory, DJ; Kip, A; Navas, A; Vargas, DA, 2016) |
| "Leishmaniasis, a fatal parasitic disease, is the second largest parasitic killer in the world and miltefosine is the first and only oral drug available for its treatment." | 3.83 | LC-coupled ESI MS for quantification of miltefosine in human and hamster plasma. ( Jaiswal, S; Lal, J; Sharma, A; Shukla, M, 2016) |
| "Miltefosine is the first oral drug used in chemotherapy against leishmaniasis." | 3.83 | Deep-sequencing revealing mutation dynamics in the miltefosine transporter gene in Leishmania infantum selected for miltefosine resistance. ( Laffitte, MC; Légaré, D; Leprohon, P; Ouellette, M, 2016) |
| "To achieve an integrated assessment of current and innovative therapeutic strategies, we determined host and parasite responses to miltefosine and meglumine antimoniate alone and in combination with pentoxifylline or CpG 2006 in peripheral blood mononuclear cells (PBMCs) of cutaneous leishmaniasis patients." | 3.81 | Ex vivo host and parasite response to antileishmanial drugs and immunomodulators. ( Fernández, OL; Gonzalez-Fajardo, L; McMahon-Pratt, D; Saravia, NG, 2015) |
| "Although oral miltefosine represented an important therapeutic advance in the treatment of leishmaniasis, the appearance of resistance remains a serious threat." | 3.77 | Sitamaquine overcomes ABC-mediated resistance to miltefosine and antimony in Leishmania. ( Bavchvarov, BI; Campillo, M; Castanys, S; Gamarro, F; López-Martín, C; Martínez-García, M; Pérez-Victoria, JM; Torrecillas, IR, 2011) |
| "This study aimed to investigate the activity of a combination of topical paromomycin gel and oral miltefosine for the treatment of experimental cutaneous leishmaniasis caused by Leishmania (Leishmania) amazonensis." | 3.76 | Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis. ( Aguiar, MG; Fernandes, AP; Ferreira, LA; Pereira, AM, 2010) |
| " Once treatment for leishmaniasis was started with miltefosine, CD4+ cell count rose above 400/microL." | 3.74 | Leishmania infection can hamper immune recovery in virologically suppressed HIV-infected patients. ( Bestetti, A; Bossolasco, S; Cernuschi, M; Cinque, P; De Bona, A; Gaiera, G; Gianotti, N; Lazzarin, A; Maillard, M, 2008) |
| "The alkylphosphocholine class of drugs, including edelfosine and miltefosine, has recently shown promise in the treatment of protozoal and fungal diseases, most notably, leishmaniasis." | 3.72 | Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine. ( Birchmore, JL; Hanson, PK; Malone, L; Nichols, JW, 2003) |
| "Oral miltefosine was administered to 39 human immunodeficiency virus (HIV)-infected patients with leishmaniasis for whom standard leishmaniasis treatment had failed." | 3.72 | Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. ( Bommer, W; Engel, KR; Fischer, C; Sindermann, H, 2004) |
| "Miltefosine has not been readily available in the United States due to marketing delays and is expected to become available later this year." | 2.52 | Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine. ( Fujinami, N; Shah, PJ; Vakil, NH, 2015) |
| "Miltefosine is an alkylphosphocholine drug with demonstrated activity against various parasite species and cancer cells as well as some pathogenic bacteria and fungi." | 2.48 | Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. ( Balasegaram, M; Beijnen, JH; de Vries, PJ; Dorlo, TP, 2012) |
| "Amiodarone is also capable to inhibit the oxidosqualene cyclase, a key enzyme in the synthesis of ergosterol." | 2.47 | Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review. ( Benaim, B; Garcia, CR, 2011) |
| "Leishmaniasis is a parasitic disease caused by hemoflagellate, Leishmania spp." | 2.44 | Chemotherapy of leishmaniasis: past, present and future. ( Mishra, J; Saxena, A; Singh, S, 2007) |
| "Oral fluconazole has been shown to be more effective than placebo in one instance: for Leishmania major cutaneous disease from Saudi Arabia." | 2.43 | Clinical status of agents being developed for leishmaniasis. ( Berman, J, 2005) |
| "Miltefosine was originally formulated and registered as a topical treatment for cutaneous cancers." | 2.43 | Development of miltefosine as an oral treatment for leishmaniasis. ( Engel, J; Sindermann, H, 2006) |
| "Fluconazole treatment for 6 weeks speeds up the already-rapid cure rate of cutaneous disease due to Leishmania major." | 2.42 | Current treatment approaches to leishmaniasis. ( Berman, J, 2003) |
| "Leishmaniasis is a parasitic disease caused by a hemoflagellate, Leishmania spp." | 2.42 | Challenges and new discoveries in the treatment of leishmaniasis. ( Singh, S; Sivakumar, R, 2004) |
| "Laryngeal leishmaniasis is an unusual form of the disease." | 1.62 | Case Report: Progressive Dysphonia and Dysphagia due to Laryngeal Leishmaniasis. ( Bakhos, D; Desoubeaux, G; Lemaignen, A; Renard, L, 2021) |
| "Leishmaniasis is a group of tropical diseases caused by protozoan parasites of the genus Leishmania." | 1.46 | Biochemical and inhibition studies of glutamine synthetase from Leishmania donovani. ( Babu, NK; Kumar, R; Kumar, V; Singh, S; Soumya, N; Yadav, S, 2017) |
| "His dysphonia was initially managed as bronchiectasis with little improvement." | 1.43 | Laryngeal leishmaniasis in a patient taking inhaled corticosteroids. ( Mukherjee, J; Phillips, D; Roberts, RM, 2016) |
| "Miltefosine was used as a control in selection experiments and both stepwise selection and chemical mutagenesis allowed successful isolation of miltefosine resistant mutants." | 1.42 | Leishmania is not prone to develop resistance to tamoxifen. ( Coelho, AC; Senra, L; Trinconi, CT; Uliana, SR; Yokoyama-Yasunaka, JK, 2015) |
| "Ocular leishmaniasis is a potentially blinding disease and delay in diagnosis and treatment can cause irreversible damage to the eye and adnexae." | 1.42 | Caruncular Leishmaniasis--An Unusual Case. ( Badri Prasad, B; Poonam, L; Shakya, A; Smriti, K, 2015) |
| "Oral treatment with miltefosine is generally well tolerated and has relatively few adverse effects." | 1.40 | Repurposing miltefosine for the treatment of immune-mediated disease? ( Hommes, DW; Peppelenbosch, MP; van den Brink, GR; Verhaar, AP; Wildenberg, ME, 2014) |
| "Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas." | 1.36 | Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010) |
| "2%) presented product-related adverse events concerning the gastrointestinal tract." | 1.35 | Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis. ( Bianciardi, P; Mateo, M; Maynard, L; Miró, G; Vischer, C, 2009) |
| "Leishmaniasis is a protozoan vector borne disease prevalent throughout the world and present in at least 88 countries." | 1.35 | Development of new antileishmanial drugs--current knowledge and future prospects. ( Le Pape, P, 2008) |
| "Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models." | 1.32 | Miltefosine (Impavido): the first oral treatment against leishmaniasis. ( Bommer, W; Croft, SL; Eibl, HJ; Engel, J; Engel, KR; Sindermann, H; Unger, C, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (32.00) | 29.6817 |
| 2010's | 44 (58.67) | 24.3611 |
| 2020's | 7 (9.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreira, BA | 1 |
| Coser, EM | 1 |
| Saborito, C | 1 |
| Yamashiro-Kanashiro, EH | 1 |
| Lindoso, JAL | 1 |
| Coelho, AC | 2 |
| Mano, C | 1 |
| Kongkaew, A | 1 |
| Tippawangkosol, P | 1 |
| Junkum, A | 1 |
| Siriyasatien, P | 1 |
| Jariyapan, N | 1 |
| Braga, SS | 1 |
| Borsari, C | 1 |
| Jiménez-Antón, MD | 1 |
| Eick, J | 1 |
| Bifeld, E | 1 |
| Torrado, JJ | 1 |
| Olías-Molero, AI | 2 |
| Corral, MJ | 1 |
| Santarem, N | 1 |
| Baptista, C | 1 |
| Severi, L | 1 |
| Gul, S | 1 |
| Wolf, M | 1 |
| Kuzikov, M | 1 |
| Ellinger, B | 1 |
| Reinshagen, J | 1 |
| Witt, G | 1 |
| Linciano, P | 1 |
| Tait, A | 1 |
| Costantino, L | 1 |
| Luciani, R | 1 |
| Tejera Nevado, P | 1 |
| Zander-Dinse, D | 1 |
| Franco, CH | 1 |
| Ferrari, S | 1 |
| Moraes, CB | 1 |
| Cordeiro-da-Silva, A | 1 |
| Ponterini, G | 1 |
| Clos, J | 1 |
| Alunda, JM | 2 |
| Costi, MP | 1 |
| Brito, JR | 1 |
| Passero, LFD | 1 |
| Bezerra-Souza, A | 1 |
| Laurenti, MD | 1 |
| Romoff, P | 1 |
| Barbosa, H | 1 |
| Ferreira, EA | 1 |
| Lago, JHG | 1 |
| Cabral, LIL | 1 |
| Pomel, S | 1 |
| Cojean, S | 1 |
| Amado, PSM | 1 |
| Loiseau, PM | 1 |
| Cristiano, MLS | 1 |
| Fontán-Matilla, E | 1 |
| Cuquerella, M | 1 |
| Tiwari, R | 1 |
| Banerjee, S | 1 |
| Tyde, D | 1 |
| Saha, KD | 1 |
| Ethirajan, A | 1 |
| Mukherjee, N | 1 |
| Chattopadhy, S | 1 |
| Pramanik, SK | 1 |
| Das, A | 1 |
| Monteiro, M | 1 |
| Prata, S | 1 |
| Cardoso, L | 1 |
| Pereira da Fonseca, I | 1 |
| Leal, RO | 1 |
| Renard, L | 1 |
| Lemaignen, A | 1 |
| Desoubeaux, G | 1 |
| Bakhos, D | 1 |
| Kumar, V | 1 |
| Yadav, S | 1 |
| Soumya, N | 1 |
| Kumar, R | 1 |
| Babu, NK | 1 |
| Singh, S | 3 |
| Ortega, V | 1 |
| Giorgio, S | 1 |
| de Paula, E | 1 |
| Ponte-Sucre, A | 2 |
| Gamarro, F | 2 |
| Dujardin, JC | 4 |
| Barrett, MP | 1 |
| López-Vélez, R | 2 |
| García-Hernández, R | 1 |
| Pountain, AW | 1 |
| Mwenechanya, R | 1 |
| Papadopoulou, B | 1 |
| Vijayakumar, S | 1 |
| Das, P | 1 |
| Fernandez-Prada, C | 2 |
| Sharma, M | 1 |
| Plourde, M | 1 |
| Bresson, E | 1 |
| Roy, G | 2 |
| Leprohon, P | 3 |
| Ouellette, M | 3 |
| Zhang, N | 1 |
| Prasad, S | 1 |
| Huyghues Despointes, CE | 1 |
| Young, J | 1 |
| Kima, PE | 1 |
| Sousa-Batista, AJ | 1 |
| Escrivani-Oliveira, D | 1 |
| Falcão, CAB | 1 |
| Philipon, CIMDS | 1 |
| Rossi-Bergmann, B | 1 |
| Calixto, SL | 1 |
| Glanzmann, N | 1 |
| Xavier Silveira, MM | 1 |
| da Trindade Granato, J | 1 |
| Gorza Scopel, KK | 1 |
| Torres de Aguiar, T | 1 |
| DaMatta, RA | 1 |
| Macedo, GC | 1 |
| da Silva, AD | 1 |
| Coimbra, ES | 1 |
| Van den Kerkhof, M | 1 |
| Van Bockstal, L | 1 |
| Gielis, JF | 1 |
| Delputte, P | 1 |
| Cos, P | 3 |
| Maes, L | 3 |
| Caljon, G | 1 |
| Hendrickx, S | 1 |
| Castelo-Branco, PV | 1 |
| Alves, HJ | 1 |
| Pontes, RL | 1 |
| Maciel-Silva, VL | 1 |
| Ferreira Pereira, SR | 1 |
| Palić, S | 1 |
| Bhairosing, P | 1 |
| Beijnen, JH | 2 |
| Dorlo, TPC | 1 |
| Basmaciyan, L | 1 |
| Azas, N | 1 |
| Casanova, M | 1 |
| Berg, M | 1 |
| Mannaert, A | 1 |
| Vanaerschot, M | 2 |
| Van Der Auwera, G | 1 |
| de la Torre, BG | 1 |
| Hornillos, V | 1 |
| Luque-Ortega, JR | 1 |
| Abengózar, MA | 1 |
| Amat-Guerri, F | 1 |
| Acuña, AU | 1 |
| Rivas, L | 2 |
| Andreu, D | 1 |
| Dumetz, F | 1 |
| Roy, S | 1 |
| Arevalo, J | 1 |
| Verhaar, AP | 1 |
| Wildenberg, ME | 1 |
| Peppelenbosch, MP | 1 |
| Hommes, DW | 1 |
| van den Brink, GR | 1 |
| Fernández, OL | 2 |
| Diaz-Toro, Y | 2 |
| Ovalle, C | 2 |
| Valderrama, L | 2 |
| Muvdi, S | 1 |
| Rodríguez, I | 1 |
| Gomez, MA | 2 |
| Saravia, NG | 3 |
| Tiwari, A | 2 |
| Kumar, S | 2 |
| Shivahare, R | 1 |
| Kant, P | 1 |
| Gupta, S | 2 |
| Suryawanshi, SN | 2 |
| Vakil, NH | 1 |
| Fujinami, N | 1 |
| Shah, PJ | 1 |
| Manna, L | 1 |
| Corso, R | 1 |
| Galiero, G | 1 |
| Cerrone, A | 1 |
| Muzj, P | 1 |
| Gravino, AE | 1 |
| Gonzalez-Fajardo, L | 1 |
| McMahon-Pratt, D | 1 |
| Badri Prasad, B | 1 |
| Shakya, A | 1 |
| Poonam, L | 1 |
| Smriti, K | 1 |
| Trinconi, CT | 1 |
| Senra, L | 1 |
| Yokoyama-Yasunaka, JK | 1 |
| Uliana, SR | 1 |
| Dohmen, LC | 1 |
| Navas, A | 1 |
| Vargas, DA | 1 |
| Gregory, DJ | 1 |
| Kip, A | 1 |
| Dorlo, TP | 2 |
| Jaiswal, S | 1 |
| Sharma, A | 1 |
| Shukla, M | 1 |
| Lal, J | 1 |
| Roberts, RM | 1 |
| Mukherjee, J | 1 |
| Phillips, D | 1 |
| Laffitte, MC | 1 |
| Légaré, D | 1 |
| Vincent, IM | 1 |
| Brotherton, MC | 1 |
| Roberts, M | 1 |
| Smith, TK | 1 |
| Ratna, A | 1 |
| Arora, SK | 1 |
| Le Pape, P | 1 |
| Gianotti, N | 1 |
| Maillard, M | 1 |
| Gaiera, G | 1 |
| Bestetti, A | 1 |
| Cernuschi, M | 1 |
| De Bona, A | 1 |
| Lazzarin, A | 1 |
| Cinque, P | 1 |
| Bossolasco, S | 1 |
| Mateo, M | 1 |
| Maynard, L | 1 |
| Vischer, C | 2 |
| Bianciardi, P | 2 |
| Miró, G | 1 |
| Vermeersch, M | 2 |
| da Luz, RI | 2 |
| Toté, K | 1 |
| Timmermans, JP | 1 |
| Brovida, C | 1 |
| Valente, M | 1 |
| Aresu, L | 1 |
| Cavicchioli, L | 1 |
| Giroud, L | 1 |
| Castagnaro, M | 1 |
| Liarte, DB | 1 |
| Murta, SM | 1 |
| Barragán, P | 1 |
| Olmo, M | 1 |
| Podzamczer, D | 1 |
| Aguiar, MG | 1 |
| Pereira, AM | 1 |
| Fernandes, AP | 1 |
| Ferreira, LA | 1 |
| Pérez-Victoria, JM | 1 |
| Bavchvarov, BI | 1 |
| Torrecillas, IR | 1 |
| Martínez-García, M | 1 |
| López-Martín, C | 1 |
| Campillo, M | 1 |
| Castanys, S | 1 |
| Machado, PR | 1 |
| Penna, G | 1 |
| Murray, HW | 1 |
| Benaim, B | 1 |
| Garcia, CR | 1 |
| Fernández, O | 1 |
| Valderrama, M | 1 |
| Castillo, H | 1 |
| Perez, M | 1 |
| Singh, N | 1 |
| Kumar, M | 1 |
| Singh, RK | 1 |
| Balasegaram, M | 1 |
| de Vries, PJ | 1 |
| Mittal, M | 1 |
| Vishwakarma, P | 1 |
| Lobovská, A | 1 |
| Nohýnková, E | 1 |
| Hanson, PK | 1 |
| Malone, L | 1 |
| Birchmore, JL | 1 |
| Nichols, JW | 1 |
| Berman, J | 3 |
| Sindermann, H | 5 |
| Croft, SL | 2 |
| Engel, KR | 3 |
| Bommer, W | 3 |
| Eibl, HJ | 2 |
| Unger, C | 1 |
| Engel, J | 3 |
| Desjeux, P | 1 |
| Fischer, C | 1 |
| Sivakumar, R | 1 |
| Kuhlencord, A | 1 |
| Sundar, S | 2 |
| Zappel, H | 1 |
| Berman, JD | 1 |
| Soto, J | 3 |
| Soto, P | 2 |
| Gutteridge, WE | 1 |
| Bryceson, AD | 1 |
| Croft, S | 1 |
| Gutteridge, W | 1 |
| Karbwang, J | 1 |
| Urbina, JA | 1 |
| Seifert, K | 1 |
| Yardley, V | 1 |
| Mishra, J | 1 |
| Saxena, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia.[NCT01462500] | Phase 4 | 60 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Evaluation of the Safety and Clinical Activity of Curaleish Lotion and Cream in the Topical Treatment of Cutaneous Leishmaniasis in Colombia[NCT04072874] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2021-01-31 | Withdrawn (stopped due to Tthe study is in the approval phase by local regulatory authorities) | ||
| Randomized Clinical Trial to Evaluate the Safety and Therapeutic Response of Two ARNICA TINCTURE Treatment Regimes in the Topical Treatment of Uncomplicated Cutaneous Leishmaniasis in Colombia[NCT05094908] | Phase 1 | 16 participants (Anticipated) | Interventional | 2023-05-03 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
25 reviews available for phosphorylcholine and Leishmaniasis
| Article | Year |
|---|---|
Multi-target drugs active against leishmaniasis: A paradigm of drug repurposing.
Topics: Amphotericin B; Antifungal Agents; Drug Repositioning; Drug Resistance, Fungal; Fluconazole; Humans; | 2019 |
Liposomal formulations in the pharmacological treatment of leishmaniasis: a review.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Compounding; Drug Delivery Systems; Drug Liberat | 2017 |
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.
Topics: Amphotericin B; Antiprotozoal Agents; Drug Resistance; Drug Therapy, Combination; Humans; Leishmania | 2017 |
Recent progress in drug targets and inhibitors towards combating leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Resistance; Humans; Leishmaniasis; Phosphorylcho | 2018 |
Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation.
Topics: Animals; Antiprotozoal Agents; Cytokines; Humans; Immunomodulation; Leishmania; Leishmaniasis; Phosp | 2019 |
(Post-) Genomic approaches to tackle drug resistance in Leishmania.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Genome, Protozoan; Genomics; Humans; Leishmania; Lei | 2013 |
Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Humans; Insect Vectors; Leishmania; Leishmaniasis; P | 2014 |
Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine.
Topics: Antiprotozoal Agents; Drug Resistance; Humans; Leishmaniasis; Leishmaniasis, Cutaneous; Leishmaniasi | 2015 |
Miltefosine and cutaneous leishmaniasis.
Topics: Administration, Oral; Antiprotozoal Agents; Clinical Trials as Topic; Humans; Leishmaniasis; Phospho | 2012 |
Leishmaniasis in the United States: treatment in 2012.
Topics: Administration, Oral; Amphotericin B; Antiprotozoal Agents; Humans; Immunocompromised Host; Injectio | 2012 |
Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review.
Topics: Amiodarone; Antiprotozoal Agents; Calcium; Chagas Disease; Homeostasis; Humans; Leishmania; Leishman | 2011 |
Leishmaniasis: current status of available drugs and new potential drug targets.
Topics: Aminoquinolines; Amphotericin B; Antigens, Protozoan; Antimony Sodium Gluconate; Antiprotozoal Agent | 2012 |
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.
Topics: Antiprotozoal Agents; Clinical Trials as Topic; Humans; Leishmania; Leishmaniasis; Phosphorylcholine | 2012 |
[New drugs for treatment of parasitic infections].
Topics: Antiparasitic Agents; Humans; Intestinal Diseases, Parasitic; Leishmaniasis; Nitro Compounds; Phosph | 2003 |
Current treatment approaches to leishmaniasis.
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Clinical Trials as Topic; Fluconazo | 2003 |
Challenges and new discoveries in the treatment of leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Humans; Leishmania; Leishm | 2004 |
Clinical status of agents being developed for leishmaniasis.
Topics: Aminoquinolines; Antiprotozoal Agents; Fluconazole; Humans; Imiquimod; Ketoconazole; Leishmaniasis; | 2005 |
Development of miltefosine for the leishmaniases.
Topics: Adult; Antiprotozoal Agents; Child; Clinical Trials as Topic; Drug Design; HIV Infections; Humans; L | 2006 |
Miltefosine: oral treatment of leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Humans; Leishmaniasis; Phosphorylcholine | 2006 |
TDR collaboration with the pharmaceutical industry.
Topics: Antiprotozoal Agents; Drug Evaluation; Drug Industry; Female; Humans; Interprofessional Relations; L | 2006 |
Development of miltefosine as an oral treatment for leishmaniasis.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Antineoplastic Agents; Antiprotozoal Age | 2006 |
Miltefosine: issues to be addressed in the future.
Topics: Abnormalities, Drug-Induced; Antiprotozoal Agents; Drug Resistance; Female; Forecasting; HIV Infecti | 2006 |
Current scenario of drug development for leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leish | 2006 |
Current scenario of drug development for leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leish | 2006 |
Current scenario of drug development for leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leish | 2006 |
Current scenario of drug development for leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leish | 2006 |
[Oral miltefosine to treat leishmaniasis].
Topics: Antiprotozoal Agents; Humans; Leishmaniasis; Phosphorylcholine | 2006 |
Chemotherapy of leishmaniasis: past, present and future.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Humans; Leishmaniasis; Phosphorylcholine | 2007 |
1 trial available for phosphorylcholine and Leishmaniasis
| Article | Year |
|---|---|
Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Female; F | 2015 |
49 other studies available for phosphorylcholine and Leishmaniasis
| Article | Year |
|---|---|
In vitro miltefosine and amphotericin B susceptibility of strains and clinical isolates of Leishmania species endemic in Brazil that cause tegumentary leishmaniasis.
Topics: Amphotericin B; Antiprotozoal Agents; Brazil; Humans; Leishmania; Leishmaniasis; Leishmaniasis, Cuta | 2023 |
In vitro susceptibility to miltefosine of amphotericin B-resistant Leishmania (Mundinia) martiniquensis.
Topics: Amphotericin B; Antiprotozoal Agents; Chronic Disease; Humans; Leishmania; Leishmaniasis; Leishmania | 2023 |
Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Drug Evaluation, Preclinical; Drug Resistance; Flavonols; | 2019 |
Antileishmanial activity and ultrastructural changes of related tetrahydrofuran dineolignans isolated from Saururus cernuus L. (Saururaceae).
Topics: Animals; Antiprotozoal Agents; Furans; Leishmania; Leishmaniasis; Lignans; Mice; Mice, Inbred BALB C | 2019 |
Synthesis and Antileishmanial Activity of 1,2,4,5-Tetraoxanes against
Topics: Animals; Antiprotozoal Agents; Leishmania donovani; Leishmaniasis; Mice; Phosphorylcholine; Tetraoxa | 2020 |
Scientometric analysis of chemotherapy of canine leishmaniasis (2000-2020).
Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Combinations; D | 2021 |
Redox-Responsive Nanocapsules for the Spatiotemporal Release of Miltefosine in Lysosome: Protection against
Topics: Animals; Antiprotozoal Agents; Humans; Leishmania donovani; Leishmaniasis; Lysosomes; Mice; Nanocaps | 2021 |
Diagnosis and clinical management of canine leishmaniosis by general veterinary practitioners: a questionnaire-based survey in Portugal.
Topics: Adult; Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Humans; Knowledge; Le | 2021 |
Case Report: Progressive Dysphonia and Dysphagia due to Laryngeal Leishmaniasis.
Topics: Aged; Amphotericin B; Antiprotozoal Agents; Deglutition Disorders; Diagnosis, Differential; Dysphoni | 2021 |
Biochemical and inhibition studies of glutamine synthetase from Leishmania donovani.
Topics: Antibodies, Protozoan; Base Sequence; DNA, Protozoan; Enzyme Activation; Enzyme Inhibitors; Escheric | 2017 |
High-throughput Cos-Seq screen with intracellular Leishmania infantum for the discovery of novel drug-resistance mechanisms.
Topics: Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Cosmids; CRISPR-Cas Systems; Drug Resistanc | 2018 |
Leishmania parasitophorous vacuole membranes display phosphoinositides that create conditions for continuous Akt activation and a target for miltefosine in Leishmania infections.
Topics: Animals; Antiprotozoal Agents; Gene Knockdown Techniques; Green Fluorescent Proteins; Intracellular | 2018 |
Broad Spectrum and Safety of Oral Treatment with a Promising Nitrosylated Chalcone in Murine Leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Chalcones; Female; Leishmania; Leishmania infan | 2018 |
Novel organic salts based on quinoline derivatives: The in vitro activity trigger apoptosis inhibiting autophagy in Leishmania spp.
Topics: Animals; Antiprotozoal Agents; Apoptosis; Autophagy; Female; Leishmania; Leishmaniasis; Macrophages; | 2018 |
Impact of primary mouse macrophage cell types on Leishmania infection and in vitro drug susceptibility.
Topics: Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Cells, Cultured; Drug Resistance; Female; I | 2018 |
Ascorbic acid reduces the genetic damage caused by miltefosine (hexadecylphosphocholine) in animals infected by Leishmania (Leishamnia) infantum without decreasing its antileishmanial activity.
Topics: Animals; Antiprotozoal Agents; Ascorbic Acid; DNA Damage; Injections, Intraperitoneal; Leishmania in | 2019 |
A potential acetyltransferase involved in Leishmania major metacaspase-dependent cell death.
Topics: Acetyltransferases; Apoptosis; Caspases; Curcumin; Leishmania major; Leishmaniasis; Phosphorylcholin | 2019 |
A BODIPY-embedding miltefosine analog linked to cell-penetrating Tat(48-60) peptide favors intracellular delivery and visualization of the antiparasitic drug.
Topics: Anthelmintics; Boron Compounds; Cell Line; Cell-Penetrating Peptides; Drug Design; Humans; Leishmani | 2014 |
Repurposing miltefosine for the treatment of immune-mediated disease?
Topics: Adaptive Immunity; Adjuvants, Immunologic; Drug Discovery; Humans; Immune System Diseases; Immunity, | 2014 |
Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia.
Topics: Adolescent; Adult; Aged; Antimony; Child; Child, Preschool; Cohort Studies; Colombia; Drug Resistanc | 2014 |
Miltefosine (Impavido) for leishmaniasis.
Topics: Antiprotozoal Agents; Drug Approval; Humans; Leishmaniasis; Phosphorylcholine; United States; United | 2014 |
Chemotherapy of leishmaniasis part XIII: design and synthesis of novel heteroretinoid-bisbenzylidine ketone hybrids as antileishmanial agents.
Topics: Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Cell Survival; Cells, Cultured; Chlorocebu | 2015 |
Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
Topics: Adolescent; Animals; Antiprotozoal Agents; Female; Humans; Immunologic Factors; Interferon-alpha; In | 2015 |
Caruncular Leishmaniasis--An Unusual Case.
Topics: Antiprotozoal Agents; Diagnosis, Differential; Eye Diseases; Humans; Leishmaniasis; Male; Middle Age | 2015 |
Leishmania is not prone to develop resistance to tamoxifen.
Topics: Animals; Antiprotozoal Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance; | 2015 |
Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: IMPACT ON INTRACELLULAR SURVIVAL OF LEISHMANIA (VIANNIA) PANAMENSIS.
Topics: ATP-Binding Cassette Transporters; Biological Transport, Active; Cell Line, Tumor; Gene Knockdown Te | 2016 |
LC-coupled ESI MS for quantification of miltefosine in human and hamster plasma.
Topics: Administration, Oral; Adult; Animals; Antiprotozoal Agents; Chromatography, High Pressure Liquid; Cr | 2016 |
Laryngeal leishmaniasis in a patient taking inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Antiemetics; Antiprotozoal Agents; Asthma | 2016 |
Deep-sequencing revealing mutation dynamics in the miltefosine transporter gene in Leishmania infantum selected for miltefosine resistance.
Topics: Alleles; Animals; Antiprotozoal Agents; High-Throughput Nucleotide Sequencing; Humans; Leishmania in | 2016 |
Different Mutations in a P-type ATPase Transporter in Leishmania Parasites are Associated with Cross-resistance to Two Leading Drugs by Distinct Mechanisms.
Topics: Amphotericin B; Antiprotozoal Agents; Drug Resistance; Humans; Leishmania infantum; Leishmaniasis; M | 2016 |
Leishmania recombinant antigen modulates macrophage effector function facilitating early clearance of intracellular parasites.
Topics: Animals; Antigens, Protozoan; Cricetinae; Disease Models, Animal; Leishmania; Leishmaniasis; Macroph | 2016 |
Development of new antileishmanial drugs--current knowledge and future prospects.
Topics: Animals; Antiprotozoal Agents; Drug Therapy, Combination; Humans; Leishmania; Leishmaniasis; Phospho | 2008 |
Leishmania infection can hamper immune recovery in virologically suppressed HIV-infected patients.
Topics: Adult; Amphotericin B; Anti-Retroviral Agents; Antiprotozoal Agents; CD4 Lymphocyte Count; HIV Infec | 2008 |
Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Bone Marrow; Dog Diseases; Dogs; Female; Inject | 2009 |
In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Cells, Cultured; Inhibitor | 2009 |
Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys.
Topics: Animals; Antiprotozoal Agents; Body Weight; Dogs; Female; Fluorescent Antibody Technique; Histocytoc | 2009 |
In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells.
Topics: Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Cells, Cultured; Flow Cytometry; Leishmani | 2009 |
Selection and phenotype characterization of potassium antimony tartrate-resistant populations of four New World Leishmania species.
Topics: Amphotericin B; Animals; Antimony Potassium Tartrate; Antiprotozoal Agents; Culture Media; Drug Resi | 2010 |
Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient.
Topics: AIDS-Related Opportunistic Infections; HIV; HIV Infections; HIV-1; Humans; Itraconazole; Leishmanias | 2010 |
Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.
Topics: Administration, Oral; Administration, Topical; Animals; Anti-Bacterial Agents; Antiprotozoal Agents; | 2010 |
Sitamaquine overcomes ABC-mediated resistance to miltefosine and antimony in Leishmania.
Topics: Aminoquinolines; Antimony; Antiprotozoal Agents; ATP-Binding Cassette Transporters; Drug Resistance, | 2011 |
Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp.
Topics: Antiprotozoal Agents; Cell Line; Humans; Leishmania; Leishmaniasis; Macrophages; Meglumine; Meglumin | 2012 |
Chemotherapy of leishmaniasis. Part IX: synthesis and bioevaluation of aryl substituted ketene dithioacetals as antileishmanial agents.
Topics: Acetals; Animals; Antiprotozoal Agents; Cricetinae; Ethylenes; Ketones; Leishmania donovani; Leishma | 2012 |
New treatment for leishmaniasis is 95% effective.
Topics: Antiprotozoal Agents; Developing Countries; Humans; India; Leishmaniasis; Phosphorylcholine; Treatme | 2002 |
Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine.
Topics: Alleles; Antiprotozoal Agents; Biological Transport; Cell Division; Cell Membrane; Cycloheximide; Do | 2003 |
Miltefosine (Impavido): the first oral treatment against leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Humans; Leishmaniasis; Phosphorylcholine | 2004 |
Leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Humans; Insect Control; Leishmania; Leishmaniasis; Paromomycin; Phosp | 2004 |
Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Female; HIV Infections; Humans; Immunocompromised | 2004 |
[Leishmaniasis--oral treatment with hexadecylphosphocholine].
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Child; Clinical Trials as Topic; Drug Resistance; | 2004 |